Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib first-line treatment for primary HLH in children
2021-006878-23Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib and corticosteroids in hereditary hemophagocytic lymphohistiocytosis (FHL), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Survival until HSCT. Started Jan 2022; status: active.
02
Drugs
ruxolitinibcorticosteroids
03
Conditions
hereditary hemophagocytic lymphohistiocytosis (FHL)
Beyond the preview
Go deeper on 2021-006878-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006878-23.